Heidrich H
Med Klin. 1978 May 26;73(21):798-800.
44 patients were treated with subcutaneous ancrod (Arwin) for peripheral arterial occlusive disease (Fontaine stage III). An acute fulminating arterial occlusion occurred in two patients on the 10th and 23rd days respectively, and in a third patient a deep venous thrombosis developed in the leg on the 45th day after beginning treatment. Accordingly, vascular occlusion must be expected during defibrination in the presence of poor peripheral drainage conditions and if the serum fibrinogen can no longer be maintained below 1.0 g/1 in spite of increasing the ancrod dosage. Under these circumstances the treatment must be terminated.
44例患有外周动脉闭塞性疾病（FontaineⅢ期）的患者接受了皮下注射安克洛酶（Arwin）治疗。分别有2例患者在第10天和第23天发生急性暴发性动脉闭塞，另有1例患者在开始治疗后第45天腿部出现深静脉血栓形成。因此，在外周引流条件差且尽管增加安克洛酶剂量血清纤维蛋白原仍无法维持在1.0g/1以下的情况下进行去纤维蛋白治疗时，必须预料到血管闭塞的发生。在这种情况下，必须终止治疗。
